
News|Articles|February 13, 2019
Revcovi for Adenosine Deaminase Severe Combined Immune Deficiency
Author(s)Drew Boxler
Advertisement
Revcovi (elapegademase-lvlr, Lediant Biosciences)
Indications: Adenosine deaminase severe combined immune deficiency (ADA-SCID)
Dosage:
- Starting: 0.4 mg/kg (idea body weight) in 2 intramuscular supplements (0.2 mg/kg twice per week)
- Maintenance dosing: increments of 0.033 mg/kg weekly if...
- trough ADA activity is under 30 mmol/hr/L
- trough deoxyadenosine nucleotides (dAXP) are above 0.02 mmol/L
- the immune reconstitution is inadequate based on the clinical assessment of the patient
Contraindications: N/A
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Pneumococcal Diseases Require Constant Vaccine Development | NCPA 2025
2
The Variety of Migraine Treatment Options Opens the Door for Pharmacy Services | NCPA 2025
3
The Rise in Supplement Use Calls for Pharmacist-Led Counseling, Education | NCPA 2025
4
Why Pharmacists Need to Put More Emphasis on Supplement Education | NCPA 2025
5